PAR 1 Pharmacology Flashcards
Ketoacidosis cause and tx
cause: LOW insulin
tx: insulin
increased ketones lower the pH and increase glucose, leading to hyperglycemic crisis
Sever HYPOglycemia treatment
recombinant glucagon
stimulates the liver to release glucose into the blood
Sulfonylureas
increase insulin release by blocking K+/ATP channels in beta cells
HIGH RISK of HYPOGLYCEMIA
- chlorpropamide
- glyburide
- glimepiride
- glipizide
What should you avoid prescribing in patients on sulfonylureas?
NSAIDs– could increase hypoglycemia
Meglitinides
“-glinide”
increase insulin release from beta cells
control of post-prandial glucose
- repaglinide
- nateglinide
Biguanides
- metformin
does NOT affect insulin secretion– NO risk of hypoglycemia
Stimulates AMPKs to reduce blood glucose
- (AMP activated protein kinase)
LACTIC ACIDOSIS RISK
Thiazolidinediones
“-glitazone”– rosiglitazone, pioglitazone
Specifically bind PPAR𝝲
increase insulin sensitivity– makes a low concentration have the same effect as a higher concentration
Metabolized by P450
Black box warning to monitor for heart failure signs after starting therapy
Ultra short insulins
aspart
lispro
glulisine
Short acting insulins
normal insulin
intermediate acting insulins
NPH
lente
Long acting insulins
detemir
degludec
glargine
What drugs have the potential to cause hypoglycemia?
- insulin therapy
- sulfonylureas
- meglitanides
Peptide incretin drugs
bind GLP-1 receptors (act like GLP-1)
decreases glycogenolysis caused by glucagon
- liraglutide
- albiglutide
- dilaglutide
- exenatide
Which peptide incretin drugs are resistant to hydrolysis by DPP4?
liraglutide
exenatide
DPP4 does what?
hydrolyzes (inactivates) incretins (so insulin is lower)
DPP4 inhibitors
increase insulin and lower blood glucose
- sitagliptin
- saxagliptin
- linagliptin
sitagliptin also inhibits inactivation of GLP-1
Colesevelam hydrochloride [Welchol]
bile acid sequestrant
- developed to lower cholesterol, now approved for type II diabetics who are taking other medications
lowers HbA1c and LDL cholesterol
Na/Glucose co-transport 2 inhibitors
“-flozin”– canagliflozin, dapagliflozin, empagliflozin
Block glucose reuptake in the kidneys by inhibiting SGLT2
Do NOT use in patients with compromised kidneys
Somatostatin action
delta cell secretion
inhibits TSH and GH release from pituitary
inhibits insulin AND glucagon release
Somatostatin drug
ocreotide
inhibit insulin in insulinomas
inhibits glucagon in glucagonomas
can also tx acromegaly
alpha-glucosidase inhibitors
acarbose, miglitol
reduces uptake of carbohydrates and decreases post-prandial glucose rise
diazoxide
potent HYPERglycemic actions
inhibits insulin secretion, but does NOT inhibit insulin synthesis
tx for inoperable insulinomas